AbbVie raises FY14 EPS guidance
Co issues in-line guidance for FY14 (Dec), sees EPS of $3.06-3.16 vs. $3.11 Capital IQ Consensus Estimate.
- AbbVie's 2014 outlook continues to exclude any potential revenue from the expected 2014 U.S. launch of its hepatitis C (HCV) therapy which has been granted accelerated review by the U.S. Food and Drug Administration (FDA).
- The co is raising its outlook, reflecting strong underlying business performance year to date and the expected continued positive trends over the remainder of the year, including the second quarter.